![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
August 23, 2021
Fall 2021 Group Meeting to be virtual; a new prevention trial; the case for COVID-19 vaccination
August 17, 2021
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
August 17, 2021
July 7, 2021
ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years
July 7, 2021
Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
ECOG-ACRIN has established a Task Force on Advancement for Women under the leadership of Barbara Burtness, MD of Yale University
July 7, 2021
Recent ECOG-ACRIN trial updates and results
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
May 28, 2021
This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes